# Biological-guided Metronomic Chemotherapy as Maintenance Strategy in Metastatic Colorectal Cancer

> **NCT03158610** · PHASE2,PHASE3 · TERMINATED · sponsor: **Ruijin Hospital** · enrollment: 20 (actual)

## Conditions studied

- Colorectal Cancer

## Interventions

- **DRUG:** Capecitabine

## Key facts

- **NCT ID:** NCT03158610
- **Lead sponsor:** Ruijin Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2018-01-29
- **Primary completion:** 2021-04-28
- **Final completion:** 2021-04-28
- **Target enrollment:** 20 (ACTUAL)
- **Why stopped:** Difficult to enrollment patient
- **Last updated:** 2021-05-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03158610

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03158610, "Biological-guided Metronomic Chemotherapy as Maintenance Strategy in Metastatic Colorectal Cancer". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT03158610. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*